Extracorporeal Membrane Oxygenation Support In COVID-19: An International Cohort Study Of The Extrac

Among patients aged 16 years or older with confirmed COVID-19 managed with extracorporeal membrane oxygenation (ECMO), researchers sought to characterize the epidemiology, hospital course, as well as outcomes. For this purpose, they utilized data from the Extracorporeal Life Support Organization Registry. In-hospital mortality in a time-to-event analysis evaluated at 90 days following ECMO start was the primary outcome. The cumulative incidence of in-hospital death 90 days following the start of ECMO was estimated to be 37·4%. ECMO use for circulatory support was identified to be independently related to higher in-hospital death. According to the findings, not only estimated mortality 90 days post-ECMO but also mortality in those with a final disposition of death or discharge were reported to be less than 40% in this study sample of patients with COVID-19 who were managed with ECMO. These observations from 213 hospitals globally afford a generalisable estimate of ECMO death in the setting of COVID-19.

Source​